aTyr Pharma, Inc.

NASDAQ:ATYR

Biotechnology

Healthcare
$0.53 +14.23%

+$0.07 today

Market cap
$52.13M
Beta
0.54
P/E (TTM)
-0.7
EPS (TTM)
-$0.71
52W Low $0.40High $7.29

Volume 1.02M

Average 2.29M

ATYR Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

aTyr Pharma, Inc.NASDAQ: ATYR

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $394K rose 2.9% year over year, behind the +35.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -2.9% a year.

Context

  • Depreciation & amortization amounted to 817.4% of revenue in FY2025, up 162.0 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +2.9% toward the trailing-twelve-month pace of +35.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$394K+0.0% QoQ
Last fiscal yearDec 2025
$1.55M+0.8% YoY
LTMMar 2026
$1.56M+35.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.9%——
1 year+0.8%——
3-year CAGR-2.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
1.55M USD
Year-over-year change
+0.8%
4-year CAGR
+4.5%

Depreciation & Amortization vs competitors

How ATYR compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +35.6% is the 2nd highest of 7, against a peer median of -11.2%.
  • Depreciation & amortization amounts to 823.2% of revenue for ATYR, versus a peer median of 12.4%.
ATYR Competitors
Depreciation & Amortization for ATYR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DTILPrecision BioSciences, Inc.LTM Mar 2026$2.69M USD-30.3%-32.6%6.0%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$2.28M CAD-57.9%+10.7%12.4%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$1.74M USD+3.4%—44.2%
ATYRaTyr Pharma, Inc.LTM Mar 2026$1.56M USD+35.6%-2.9%823.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$1.21M USD+8.3%+36.2%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$648K USD+132.3%+52.6%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$645K USD-25.8%+27.3%—
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ATYR) —-11.2%+27.3%12.4%

Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(33.77M)(45.34M)(50.39M)(64.02M)(74.12M)
Depreciation & Amortization1.3M1.7M2.74M1.54M1.55M
Deferred Income Tax00000
Stock-Based Compensation1.61M2.15M2.6M2.99M5M
Change in Working Capital(2.59M)(833K)15.01M(6.92M)7.45M
Accounts Receivables1.6M(11.92M)9.05M402K863K
Inventory00000
Accounts Payables47K03.26M(1.34M)(33K)
Other Working Capital(4.24M)11.09M2.7M(5.98M)6.62M
Other Non-Cash Items363K441K(3.19M)(2.71M)(1.87M)
Operating Cash Flow(33.08M)(41.89M)(33.22M)(69.12M)(61.99M)
Capital Expenditures(192K)(1.64M)(4.22M)(65K)(77K)
Acquisitions (Net)50K007K12K
Purchases of Investments(126.51M)(42.12M)(106.98M)(69.1M)(93.45M)
Sales of Investments35.08M90.83M91.05M86.39M86.6M
Other Investing Activities0179K15K01.85M
Investing Cash Flow(91.57M)47.25M(20.13M)17.23M(5.05M)
Debt Repayment0(66K)(394K)(497K)(539K)
Common Stock Issued109.95M5.47M66.52M40.26M66.42M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities73K45K105K100K0
Financing Cash Flow110.03M5.45M66.23M39.86M66.01M
Effect of Forex Changes00000
Net Change in Cash(14.62M)10.81M12.88M(12.02M)(1.03M)
Free Cash Flow(33.27M)(43.53M)(37.44M)(69.18M)(62.06M)

aTyr Pharma, Inc.

NASDAQ:ATYR

Intrinsic Alpha fair value

Locked

Current Price

$0.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.